Abstract:Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent in vitro cyto- and hemocompatibility.

[Evaluation of Blood Compatibility of Surface Modification Treated Poly (D, L-lactic and Glycolic Acid) with Mpeg Block Copolymer].

Evaluation of blood compatibility of MeO-PEG-poly (D,L-lactic-co-glycolic acid)-PEG-OMe triblock copolymer

Lipid-like Diblock Copolymer As an Additive for Improving the Blood Compatibility of Poly(lactide-co-glycolide)

Blood compatibility evaluation of poly(D,L-lactide-co-beta-malic acid) modified with the GRGDS sequence.

The biocompatibility evaluation of mPEG-PLGA-PLL copolymer and different LA/GA ratio effects for biocompatibility.

Blood compatibility evaluations of poly(ethylene glycol)–poly(lactic acid) copolymers

Hemocompatibility evaluation in vitro of methoxy polyethyleneglycol-polycaprolactone copolymer solutions.

Cytotoxicity and Hemocompatibility of A Family of Novel Meo-Peg-Poly (D,l-Lactic-co-glycolic Acid)-Peg-Ome Triblock Copolymer Nanoparticles

Study on the Preparation and Properties of Novel Poly (Γ-Benzyl-l-glutamate)-co-poly (ethylene Glycol)

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications

Blood Compatibility of Biomaterial Surfaces Modified with PEG and Its Derivatives

BIOCOMPATIBILITY STUDIES ON GRGDS SEQUENCE MODIFIEDPOLY(D, L-LACTIDE- Co-Β-malic ACID)

Synthesis of Copolymers Using Dendronized Polyethylene Glycol and Assay of Their Blood Compatibility and Antibacterial Adhesion Activity

In Vitro Blood Compatibility of Poly (Hydroxybutyrate-Co-hydroxyhexanoate) and the Influence of Surface Modification by Alkali Treatment

Biocompatible Poly(ethylene Glycol)‐poly(γ‐cholesterol‐l‐glutamate) Copolymers: Synthesis, Characterization, and in Vitro Studies

In Vitro Biocompatibility Evaluation of Bioresorbable Copolymers Prepared from L-Lactide, 1, 3-Trimethylene Carbonate, and Glycolide for Cardiovascular Applications

Improved Blood Compatibility of Polyethersulfone Membrane with A Hydrophilic and Anionic Surface

Blood compatibility of a new type of EPC capture coronary stent coating in vitro

STUDY ON POLY(LACTIC ACID) MODIFIED BY POLYETHYLENE GLYCOL

Surface Modification and in Vitro Blood Compatibilities of Polyurethanes Containing Γ‐benzyl L‐glutamate Segments in the Main Chain

Facile Surface Modification of Glass with Zwitterionic Polymers for Improving the Blood Compatibility